RAGGI, DANIELE
RAGGI, DANIELE
Universita' degli Studi di MILANO
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma
2016 P. Pinciroli, H. Won, G. Iyer, S. Canevari, M. Colecchia, P. Giannatempo, D. Raggi, M.A. Pierotti, F.G. De Braud, D.B. Solit, J.E. Rosenberg, M.F. Berger, A. Necchi
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
2016 A. Necchi, S. Lo Vullo, L. Mariani, D. Raggi, P. Giannatempo, G. Calareso, E. Togliardi, F. Crippa, N. Di Genova, F. Perrone, M. Colecchia, B. Paolini, G. Pelosi, N. Nicolai, G. Procopio, R. Salvioni, F.G. De Braud
Immunotherapy advances in uro-genital malignancies
2016 R. Ratta, R. Zappasodi, D. Raggi, P. Grassi, E. Verzoni, A. Necchi, M. Di Nicola, R. Salvioni, F. de Braud, G. Procopio
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma.
2015 N. Nicolai, E. Bianchi, I. Donati, C. L’Acqua, C. Brunelli, D. Biasoni, M. Catanzaro, S. Stagni, L. Piva, T. Torelli, A. Necchi, D. Raggi, P. Giannatempo, E. Faré, M. Colecchia, M. Langer, C. Borreani, R. Salvioni
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy
2015 A. Necchi, P. Giannatempo, B. Paolini, S. Lo Vullo, M. Marongiu, E. Farè, D. Raggi, N. Nicolai, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, M. Maffezzini, A.M. Gianni, F. De Braud, L. Mariani, G. Sonpavde, M. Colecchia, R. Salvioni
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes
2015 P. Giannatempo, T. Greco, L. Mariani, N. Nicolai, S. Tana, E. Farè, D. Raggi, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, B. Avuzzi, M. Maffezzini, G. Landoni, F. De Braud, A.M. Gianni, G. Sonpavde, R. Salvioni, A. Necchi
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation
2015 D. Raggi, L. Mariani, P. Giannatempo, S. Lo Vullo, D. Giardiello, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Calareso, M. Magni, M. Di Nicola, E. Verzoni, P. Grassi, G. Procopio, F. De Braud, G. Pizzocaro, R. Salvioni, A. Necchi
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
2015 E. Zanardi, E. Verzoni, P. Grassi, A. Necchi, P. Giannatempo, D. Raggi, F. De Braud, G. Procopio
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer
2014 A. Necchi, L. Mariani, P. Giannatempo, D. Raggi, E. Farè, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Pizzocaro, F.G. De Braud, A.M. Gianni, R. Salvioni
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial
2014 A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M.G. Daidone, A.M. Gianni, R. Salvioni, F. De Braud
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment
2013 P. Giannatempo, B. Paolini, R. Miceli, D. Raggi, N. Nicolai, E. Faré, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, L. Piva, L. Mariani, R. Salvioni, M. Colecchia, A.M. Gianni, A. Necchi
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes
2013 A. Necchi, N. Nicolai, L. Mariani, D. Raggi, E. Farè, P. Giannatempo, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, A. Milani, L. Piva, G. Pizzocaro, A.M. Gianni, R. Salvioni